Real-world study compares biologics for preventing Crohn's recurrence post-surgery

A population-based retrospective cohort study from Calgary examined 231 adults with Crohn's disease who underwent ileocolonic resection between 2016 and 2020, comparing biologic prophylaxis strategies against no treatment for preventing endoscopic recurrence within 18 months. After adjustment for known risk factors, the study reported that TNF antagonists, ustekinumab, and vedolizumab were all associated with reduced odds of endoscopic recurrence compared with no treatment, and that vedolizumab was associated with lower recurrence odds than ustekinumab but not significantly different from TNF antagonists. The authors concluded that both ustekinumab and vedolizumab appeared effective, including in patients with prior TNF exposure.

Most relevant for: Adults with Crohn's disease undergoing ileocolonic resection who require postoperative recurrence prevention strategies, including those with prior TNF antagonist exposure.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.